Methergin

Methylergometrine Maleate, the active ingredient in Methergin, is an ergot alkaloid presented as an injectable solution for intramuscular or intravenous use. It is employed to prevent and treat postpartum hemorrhage by promoting uterine contraction in women after delivery.

GNH USA supplies Methergin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical support throughout the procurement process.

Methergin is a uterotonic agent used in obstetric care to manage bleeding related to childbirth.

- Prevention of postpartum hemorrhage: Reduces the risk of excessive bleeding by stimulating uterine contraction immediately after delivery. - Treatment of postpartum hemorrhage: Controls active bleeding when uterine atony occurs following birth. - Control of uterine bleeding after delivery: Assists in achieving hemostasis during the early postpartum period.

Methergin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after injection. - Hypertension: transient increase in blood pressure. - Headache: mild to moderate intensity. - Abdominal pain: cramp‑like discomfort. - Flushing: temporary reddening of skin.

Serious or Rare Side Effects: - Coronary artery spasm: chest pain with possible ischemia. - Myocardial infarction: rare heart attack events. - Severe hypertension: rapid and dangerous rise in blood pressure. - Seizures: uncommon neurologic events. - Pulmonary edema: fluid accumulation in lungs. - Allergic reactions: including anaphylaxis and severe skin rash.

Before using Methergin, clinicians should consider several safety measures.

- Assess cardiovascular status: monitor blood pressure and heart rate before and during administration. - Evaluate for hypertension: avoid use in patients with uncontrolled high blood pressure. - Review drug history: contraindicated with MAO inhibitors and other ergot alkaloids. - Monitor for signs of ischemia: watch for chest pain or ECG changes. - Use caution in patients with coronary artery disease: consider alternative therapies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methergin can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertensive crisis. - Other ergot alkaloids (e.g., ergotamine): additive vasoconstriction. - Potent CYP3A4 inhibitors: increased plasma levels of methylergometrine.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: may require dose adjustment due to blood pressure changes. - Serotonergic drugs: potential for serotonin syndrome. - Hepatic enzyme inducers: may reduce drug efficacy. - Calcium channel blockers: possible additive cardiovascular effects.